by Massimo Sandal (Agenzia Zoe)

Takeaway messages

• A hypomethylating agent (HMA) plus venetoclax combination therapy ( HMA+Ven) should be preferentially considered for patients with treated secondary acute myeloid leukemia (ts-AML), prior HMA exposure and no adverse risk karyotypes...